Viking to charge quickly into phase 3 with obesity med

Jul 25, 2024 · Viking's obesity med set to charge into phase 3, with $300M earmarked for clinical program. By Annalee Armstrong Jul 25, 2024 9:19am. Viking Therapeutics Earnings obesity …

CouponFollow Extension

$300
OFF

Viking To Charge Quickly Into Phase 3 With Obesity Med

6 days from now

Jul 25, 2024 · Viking's obesity med set to charge into phase 3, with $300M earmarked for clinical program. By Annalee Armstrong Jul 25, 2024 9:19am. Viking Therapeutics Earnings obesity …

fiercebiotech.com

$300
OFF

Viking’s Obesity Med Set To Charge Into Phase 3, With $300M …

6 days from now

Oct 30, 2024 · With the application approved, Viking has already completed dose escalation for cohorts of patients taking 60 mg or 80 mg daily. Elsewhere, a 100-mg group is ongoing. The …

biotech-insider.com

8%
OFF

Viking Oral Obesity Med Posts 6.8% Weight Loss For Highest Dose

6 days from now

Nov 4, 2024 · Viking's obesity med set to charge into phase 3, with $300M earmarked for clinical program. Viking also used the ObesityWeek conference to unveil further data for its injectable …

fiercebiotech.com

3%
OFF

Viking Therapeutics' Early Clinical Data Continue To Build Case For …

6 days from now

Nov 4, 2024 · This past spring, Viking reported preliminary Phase 1 data for oral VK2735 showing an average placebo-adjusted weight loss of 3.3% after 28 days. In those results, the highest of …

medcitynews.com

30%
OFF

Viking Shares Jump On Plans To Speed Obesity Drug Into Late-stage ...

6 days from now

Jul 25, 2024 · Viking Therapeutics shares soared by more than 30% early Thursday after the company told investors it’s moving an experimental obesity drug into Phase 3 testing earlier …

biopharmadive.com

$300
OFF

Viking's Obesity Drug Advancing To Phase 3 With $300M For Trials

6 days from now

Aug 1, 2024 · Viking Therapeutics is accelerating its plans to advance its obesity drug VK2735 into phase 3 trials, with the clinical program estimated to exceed $300 million. Having gained …

patsnap.com

1%
OFF

Viking Therapeutics Obesity Drug's Data Raise Best-in-Class ...

6 days from now

Feb 27, 2024 · An experimental Viking Therapeutics obesity drug that hits the same targets as a commercialized Eli Lilly medication has clinical data showing it led to an average 13.1% weight …

medcitynews.com

$300
OFF

Viking's Obesity Med Set To Charge Into Phase 3, With $300M …

6 days from now

Oct 30, 2024 · Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. The …

biotech-today.com

8%
OFF

Viking Therapeutics Is More Than Just A Weight-loss Stock, And

6 days from now

The 100 mg dose also produced weight loss of up to 6.8% compared with placebo. Viking’s stock was up 1.8% Wednesday and has gained 182% in the year to date, while the SPDR S&P …

msn.com

FAQs about Viking to charge quickly into phase 3 with obesity med Coupon?

Will Viking Therapeutics' obesity drug hold up in a Phase 3 clinical trial?

The weight loss achieved by Viking Therapeutics’ obesity drug tops results posted by Eli Lilly’s Zepbound in its pivotal test. But Viking still needs to show its results can hold up in a larger Phase 3 clinical trial. ...

Does Viking have an obesity pill?

Viking’s last update on its obesity pill was in early November at Obesity Week, an event organized by the Obesity Society. The company said obese adults taking the highest dose in a Phase 1 trial of 100 milligrams had an average weight loss of 8.2% from baseline over a four-week period. ...

Will Viking's drug help you lose weight?

That drug led to less than 10% absolute weight loss at all doses at the 13-week mark of its Phase 3 clinical trial. Viking’s drug will still need to show its results can be replicated in a larger a Phase 3 test. ...

Could Viking Therapeutics' oral obesity drug be better than wegovy & zepbound?

Michael M. Santiago via Getty Images New results from a small study of Viking Therapeutics’ oral obesity drug raised expectations among Wall Street analysts that the experimental tablet could prove superior among the growing ranks of would-be competitors to the popular weight loss treatments Wegovy and Zepbound. ...

Can Viking Therapeutics beat Eli Lilly?

An experimental Viking Therapeutics obesity drug that hits the same targets as a commercialized Eli Lilly medication has clinical data showing it led to an average 13.1% weight loss after 13 weeks of treatment, results that indicate it could compete favorably with the pharmaceutical giant’s product and others on the market. ...

Has Viking completed a dose escalation program?

Viking has already completed dose escalation for cohorts of patients taking 60 mg or 80 mg daily. Elsewhere, a 100-mg group is ongoing. With the application approved, Viking plans to initiate a larger phase 2 test in the fourth quarter of this year, Lian said. ...